Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US OTC > Cannabis >

Nemus Bioscience, Inc. (NMUS)

Add NMUS Price Alert      Hide Sticky   Hide Intro
Moderator: Paulieme, miracleshappen
Search This Board: 
Last Post: 9/24/2017 12:26:19 PM - Followers: 114 - Board type: Free - Posts Today: 4


 NEMUS BIOSCIENCE™ provides pharmaceutical research and development services focused on discovering, developing, and commercializing new chemical entities from a class of chemically diverse compounds. We develop novel and proprietary classes of product candidates that are designed to improve therapeutic options through enhanced chemical engineering that allow drug candidates to have more predictable bioavailability and pharmacokinetics leading to optimized efficacy and safety.

NEMUS Bioscience Inc., a Nevada corporation, is a SEC fully reporting company listed on the  under the symbol NMUS.

Company Website:

Filings and disclosure with Level 2 quotes:


(949) 396-0330


Nemus Bioscience (NMUS) Presentation (47 minutes):

Presentation at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City September 12th, 2016:


Major press releases:

A Sit Down With Nemus Bioscience; Cannabinoids In Focus Feb. 1, 2017 11:06 AM ET Nemus Bioscience, Inc. (NMUS)  

Nemus Bioscience Announces Milestones in the Development of Fully Synthetic Clinical-Grade Active Pharmaceutical Ingredient (API) for Drug Candidates NB1111 and NB2111 and Formulation Contract with AMRI and Catalent Pharma Solutions -

Cannabinoid Drug Advancements Take Off After Quantum Shift in U.S. Drug Policy

Nemus Bioscience Announces Presentation of NB1111 Impact on Intraocular Pressure (IOP) in Normotensive Ocular Model at the National Meeting of the American Association of Pharmaceutical Scientists (AAPS)


Nemus Bioscience Announces Enhanced Ocular Tissue Concentration by the Proprietary Prodrug of Tetrahydrocannabinol (NB1111) - Associated With a Superior Decline in Intra-Ocular Pressure (IOP) in an Animal Model


Nemus Bioscience, Inc. Announces Letter of Intent to License Biosynthetic Technology to Manufacture Its Proprietary Cannabinoid Molecules From Teewinot Life Sciences Corp.

NEMUS Bioscience Identifies Unique Cannabidiol (CBD) Derivative as a Lead Candidate in Its Neuropathy-Related Pain Management Program 

CANNAINVESTOR Magazine Top 20 Cannabis Stocks 


NEMUS Bioscience CEO to Present at the 28th Annual ROTH Conference 


NEMUS Bioscience, Inc. Signs Agreement With Albany Molecular Research Inc. (AMRI) to Manufacture Cannabinoid-Based Active Pharmaceutical Ingredients 


NEMUS Bioscience Prodrug of THC (NB1111) Completes Validation Stage of Glaucoma Testing and Development 


Nemus Enters Into Research Agreement With the University of Mississippi to Develop Cannabinoid-Based Therapies for Chemotherapy-Induced Peripheral Neuropathy (CIPN) 


NMUS Security Details

Share Structure - as of Feb 1, 2017

Authorized Shares: 236,000,000
Outstanding Shares: 
      - Restricted  13,494,621
    - Unrestricted   8,943,542

           - Float   5,005,713 a/o Mar 23, 2016 
   Par Value 0.001

Transfer Agent: Clear Trust, LLC

Cannabis Stocks News
Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NMUS News: MJAC 2017 Speaker Update - How venture capital and cryptocurrency are converging as the future of cannabis investing 08/30/2017 10:29:33 PM
NMUS News: PotNetwork Holdings, Inc Confirmed for MJAC 2017 08/28/2017 10:43:55 AM
NMUS News: MJAC 2017 International Cannabis Conference - Discount Code 08/25/2017 06:50:56 PM
NMUS News: MJAC 2017 International Cannabis Conference - Discount Code 08/24/2017 08:40:00 AM
NMUS News: Book your ticket now for InvestorsHubs International Cannabis Conference 08/23/2017 12:50:25 PM
#2772   short term pop in play, hope you collected chico hombre2 09/24/17 12:26:19 PM
#2771   My manufacturing? What are you talking about? cjarmstrong 09/24/17 01:43:14 AM
#2770   'Valeant acquired Cesamet from Eli Lilly in 2004 AntonChigurh 09/24/17 01:18:01 AM
#2769   $4 a share would be a 440m market cap AntonChigurh 09/24/17 12:22:02 AM
#2768   The financing would add 67mm shares. cjarmstrong 09/23/17 03:16:32 PM
#2767   If the right news comes out with the overtheedge 09/21/17 08:47:25 PM
#2766   You sound like a noob. They want to cjarmstrong 09/21/17 07:18:54 PM
#2765   Dilution is one of the biggest risks in cjarmstrong 09/21/17 07:14:20 PM
#2764   chicos back fellas, lets pop .32 and run chico hombre2 09/21/17 05:57:36 PM
#2763   And the reverse Split is Fake news They do AntonChigurh 09/21/17 12:32:06 PM
#2762   They are a small cap biotech No such thing AntonChigurh 09/21/17 12:30:45 PM
#2761   I think you're right, Anton. Schneider only has cjarmstrong 09/21/17 11:44:20 AM
#2760   nothing since August 7 AntonChigurh 09/18/17 08:29:54 PM
#2759   if your answer to a question about the AntonChigurh 09/14/17 04:54:29 PM
#2758   kinda dramatic AntonChigurh 09/14/17 04:39:57 PM
#2757   This is excruciatingly painful. Closewatcher 09/14/17 01:11:47 PM
#2756   Not sure but I've heard he's difficult to Vinpat 09/13/17 06:18:15 PM
#2755   I really don't like it either. Bogart and AntonChigurh 09/13/17 06:08:26 PM
#2754   I doubt it had much impact on the Vinpat 09/13/17 05:51:44 PM
#2753   Vinpat, how much damage did those traders do? AntonChigurh 09/13/17 03:07:33 PM
#2752   Let us know if you find anything out, cjarmstrong 09/13/17 02:12:53 PM
#2751   If it falls through I'm sure they have cjarmstrong 09/12/17 12:44:45 PM
#2750   28 days Until Schneider needs to pay No PR since AntonChigurh 09/12/17 10:27:32 AM
#2749   What's going on with this. Any updates? Doc Strange 09/12/17 10:25:52 AM
#2748   just to be clear AntonChigurh 09/10/17 11:16:37 PM
#2747   just to be clear AntonChigurh 09/10/17 11:16:37 PM
#2746   I took a quick look and didn't see cjarmstrong 09/09/17 01:53:36 AM
#2745   No advisors have equity AFAIK Never announced in PR AntonChigurh 09/08/17 09:57:06 PM
#2744   What costs? Advisers usually are paid in equity cjarmstrong 09/08/17 09:06:40 PM
#2743   Maybe they couldn't afford the costs involved on AntonChigurh 09/08/17 02:13:25 PM
#2742   Robert Weinreb was removed from Nemus' site sometime cjarmstrong 09/08/17 01:20:38 PM
#2741   They don't do fake news Or news for the AntonChigurh 09/08/17 11:11:06 AM
#2739   Those are questions only Nemus could answer. cjarmstrong 09/07/17 06:46:23 PM
#2738   Why did Dr. Weinreb leave Nemus? He appears in AntonChigurh 09/07/17 01:48:27 PM
#2737   With this low pps and share count, in retired early 09/05/17 02:56:57 PM
#2736   It is new. AntonChigurh 09/05/17 02:19:16 PM
#2735   NEW ARTICLE: Closewatcher 09/05/17 12:02:12 PM
#2734   Nemus Bioscience CEO Talks 'Waves Of Dominance' In AntonChigurh 09/05/17 12:01:45 PM
#2733   Can always count it on the crooks to Closewatcher 09/05/17 10:44:26 AM
#2732   You too. Thank you. Vinpat 09/01/17 03:56:48 PM
#2731   Thank you! Have a good weekend, I guess TURCH 09/01/17 03:51:24 PM
#2730   I have no clue why unless there's some Vinpat 09/01/17 03:50:23 PM
#2729   I came to say the same thing. The Jdanger 2 09/01/17 03:35:10 PM
#2728   Some serious interest today??? Regards TURCH 09/01/17 03:17:25 PM
#2727   My understanding is the agreements were similar to Vinpat 08/31/17 02:26:36 AM
#2726   Vinpat, while your here The licensing agreements. The 60/40 AntonChigurh 08/31/17 02:11:40 AM
#2725   Man you're good. Skibinski is brilliant and has Vinpat 08/31/17 02:02:56 AM
#2724   I finnaly found some info about one of AntonChigurh 08/31/17 01:44:02 AM
#2723   From-DollarsOnPennies - 08/29/17 01:39:39 AM Paulieme 08/30/17 06:58:11 PM
#2722   The financing was set to close July 10th. Schneider AntonChigurh 08/30/17 03:39:55 PM